• {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%selfProduct%}
      • {%languages%}
    • The study evaluated 2 doses of upadacitinib, 15 mg and 30 mg QD. The results presented here are for RINVOQ (upadacitinib) 15 mg once daily, which is the approved dose for Rheumatoid Arthritis.

      SELECT-NEXT: Study design

      A Phase 3 study investigating the efficacy and safety of RINVOQ + csDMARDs compared to placebo + csDMARDs in patients with moderate to severe RA and an inadequate response to csDMARDs1

      Primary
      RINVOQ 15 mg + csDMARD(s) vs placebo + csDMARD(s) at Week 12 for DAS28 (CRP) <3.2 or ACR20

      Safety
      Adverse events, serious adverse events, adverse events of special interest (e.g., serious infections, opportunistic infections, MACEs, VTEs, malignancies)

      ACR: American College of Rheumatology; ACR20: improvement of at least 20% in the American College of Rheumatology core criteria; csDMARD: conventional synthetic disease-modifying antirheumatic drug; DAS28 (CRP): disease activity score with 28 joint count (C-reactive protein); MACE: major adverse cardiovascular event; MTX: methotrexate; QD: once daily; VTE: venous thromboembolic event.

      RINVOQ 15 mg: Efficacy with csDMARDS after inadequate response to csDMARDS 

      SELECT-NEXT: Low disease activity and remission at Week 12 in patients with an inadequate response to csDMARDs (NRI)1,2

      *P≤0.001 vs placebo + csDMARD(s) 

      csDMARD: conventional synthetic disease-modifying anti-rheumatic drug; DAS28 (CRP): disease activity score with 28 joint count (C-reactive protein); NRI: nonresponder imputation.

       

      SELECT-NEXT: Adverse events through 12 weeks of treatment1

      *One case of congestive cardiac failure, one cardiovascular procedure.

       

      Jeg vil gjerne ha mer informasjon fra en produktspesialist.

      Jeg har spørsmål til medisinsk avdeling.

      Felleskatalogteksten finner du her

      Referanser

      1. Burmester GR, Kremer JM, Van den Bosch F, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10139):2503‍-‍2512. doi:10.1016/S0140-6736(18)31115-2
      2. RINVOQ SPC avsnitt 5.1, sist oppdatert 21.05.2022.

       

      NO-RNQ-200014v2.0juni/2021